Maintenance Treatment with Guadecitabine (SGI-110) in High Risk MDS and AML Patients after Allogeneic Stem Cell Transplantation

被引：1
|
作者：
Oran, Betul
Alatrash, Gheath
Alousi, Amin M.
Mehta, Rohtesh S.
Hosing, Chitra
Popat, Uday R.
Im, Jin S.
McCarty, Jessica M.
Ramos, Jennifer D.
Keer, Harold N.
Thall, Peter F.
Champlin, Richard E.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134272
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Circulating tumor DNA predicts relapse after allogeneic hematopoietic stem cell transplantation in AML and MDS
    Nakamura, Sousuke
    Yokoyama, Kazuaki
    Kondoh, Kanya
    Takei, Tomomi
    Shimizu, Eigo
    Kasajima, Rika
    Yamaguchi, Rui
    Imoto, Seiya
    Miyano, Satoru
    Tojo, Arinobu
    CANCER SCIENCE, 2018, 109 : 651 - 651
  • [42] Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine
    Graef, Thorsten
    Kuendgen, Andrea
    Fenk, Roland
    Zohren, Fabian
    Haas, Rainer
    Kobbe, Guido
    LEUKEMIA RESEARCH, 2007, 31 (02) : 257 - 259
  • [43] Second Allogeneic Stem-Cell Transplantation (SCT) From a Different Donor for the Treatment of Relapsed AML and MDS After a Previous Allogeneic SCT
    Shimoni, Avichai
    Shem-Tov, Noga
    Volchek, Yulia
    Yerushalmi, Ronit
    Nagler, Arnon
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (02) : S229 - S229
  • [44] Second allogeneic stem-cell transplantation (SCT) from a different donor for the treatment of relapsed AML and MDS after a previous allogeneic SCT
    Shimoni, A.
    Shem-Tov, N.
    Volchek, Y.
    Yerushalmi, R.
    Nagler, A.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S248 - S249
  • [45] Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML
    Legrand, F.
    Le Floch, A-C
    Granata, A.
    Fuerst, S.
    Faucher, C.
    Lemarie, C.
    Harbi, S.
    Bramanti, S.
    Calmels, B.
    El-Cheikh, J.
    Chabannon, C.
    Weiller, P-J
    Vey, N.
    Castagna, L.
    Blaise, D.
    Devillier, R.
    BONE MARROW TRANSPLANTATION, 2017, 52 (04) : 620 - 621
  • [46] Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML
    F Legrand
    A-C Le Floch
    A Granata
    S Fürst
    C Faucher
    C Lemarie
    S Harbi
    S Bramanti
    B Calmels
    J El-Cheikh
    C Chabannon
    P-J Weiller
    N Vey
    L Castagna
    D Blaise
    R Devillier
    Bone Marrow Transplantation, 2017, 52 : 620 - 621
  • [47] ROLE OF ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION IN OLDER PATIENTS WITH AMLOR HIGH RISK MDS
    Aoyama, Yasutaka
    Manabe, Masahiro
    Kumura, Takeo
    Harada, Naonori
    Nagasaki, Johzi
    Ohkita, Junya
    Mugitani, Atsuko
    ANNALS OF ONCOLOGY, 2014, 25
  • [48] Evaluation of different maintenance treatment strategies after allogeneic hematopoietic stem cell transplantation in flt3 positive AML patients
    Stauffer, E.
    Fraccaroli, A.
    Drolle, H.
    von Bergwelt, M.
    Tischer, J.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 119 - 119
  • [49] Indications for allogeneic stem cell transplantation in patients with AML
    Passweg, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 227 - 227
  • [50] Microbiota analysis in allogeneic stem cell transplant patients with in AML and MDS
    Gurer, Ekin Ece
    Oguz, Fatma Savran
    Aktas, Zerrin
    Kalayoglu, Sevgi Besisik
    Oncul, Mustafa Oral
    Sezerman, Osman Ugur
    Ekren, Berkay
    Caliskan, Kader
    Gulbas, Zafer
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2021, 51 : 326 - 326
12345